Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Prion-Like Protein Controls PTSD Symptoms in Female Mice

Researchers at Columbia University’s Mortimer B. Zuckerman Mind Brain Behavior Institute report that a prion-like protein, encoded by a gene called TIA1, helps the brain keep fearful memories in check. Without this gene, female mice exhibit the tell-tale signs

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Researchers at Columbia University’s Mortimer B. Zuckerman Mind Brain Behavior Institute report that a prion-like protein, encoded by a gene called TIA1, helps the brain keep fearful memories in check. Without this gene, female mice exhibit the tell-tale signs of post-traumatic stress disorder, or PTSD.

The results of this study (“Genetic perturbation of TIA1 reveals a physiological role in fear memory”), published in Cell Reports, point to TIA1 as a new target in the fight against PTSD, which is about twice as common in women as in men.

“Deciphering the interplay between biology and environment that gives rise to all psychiatric disorders, including PTSD, has proven incredibly difficult,” said Eric R. Kandel, MD, who is university professor and co-director of the Institute, as well as Kavli Professor of brain science at Columbia. “Today’s discovery about TIA1 has uncovered one such key component to that interplay. Our research offers a promising way forward for developing treatments that mitigate the underlying causes of PTSD and other related psychiatric illnesses.”

Prions were originally described in the context of neurological conditions called transmissible spongiform encephalopathies, which include mad cow disease in cattle and Creutzfeldt-Jakob disease in people. In these diseases, the misfolded prions clump together inside neurons, forming large aggregates that cause the neurons to degrade and die. Upon neuronal death, the prions are released and infect neighboring cells, much like a virus. Over time, this process leads to sometimes deadly neurological symptoms.

But in 2003, Kandel and his team discovered that some prions are not dangerous, but functional, and can play important biological roles. For example, in 2015, Kandel and colleagues discovered that the functional prion CPEB3 helps the brain maintain long-term memories. TIA1 is another such functional prion. It helps neurons cope with cellular stress.

“When neurons undergo stress, such as in response to a viral infection, the TIA1 protein sequesters nonessential biomolecules inside the cell,” said Joseph Rayman, PhD, who is an associate research scientist in the Kandel lab at the Institute and the paper’s first author. “This allows the cell to focus all its efforts on fighting the stress.”

To find out, the researchers changed the amount of TIA1 in the ventral hippocampus of both male and female mice. The scientists then trained the mice to associate an innocuous smell, that of ethanol, with a stressful experience. When placed in other ethanol-scented environments, the animals exhibited avoidance behavior: they tended to move away from the stressful scent.

But when the researchers removed TIA1, they saw a change in behavior, a change that was restricted to female mice. Removing TIA1 appeared to have no effect on the males, but the females’ avoidance behavior skyrocketed; their fearful memories were heightened significantly.

The researchers argue that this marked sex difference may be an essential key to uncovering why the prevalence of PTSD is so much higher in women, as compared to men. It also emphasizes the importance of including female mice in scientific research, a practice that has long been discouraged by the scientific community.

Psychiatric disorders are notoriously complex. They are thought to be linked to many genes, each of which contributes only a small amount to the problem. But Kandel and Rayman are confident that their work can be extended to identify and treat disorders in people. For example, PTSD can ultimately be traced back to abnormal processing of fear memory. And the same brain regions responsible for fear memory in mice are responsible for fear memory in people.

“Not only that, but the gene that encodes TIA1 in mice also exists in the human genome,” said Rayman. “To search for links between TIA1 activity levels and stress responses in humans, we are currently analyzing DNA from individuals in Sweden.”

“We hope our work, combined with the work of others, will lead to the identification of a large number of genes, each of which contributes a certain amount of PTSD risk,” said Kandel, who is also a senior investigator at the Howard Hughes Medical Institute. “Advances in computational and theoretical modeling could soon allow us to look at a person’s particular genetic composition and identify his or her risk for developing a psychiatric disorder, such as PTSD, and then offer the best way to treat it at the molecular level.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →